Stock listing
Frankfurt:DR6 ACADIA Pharmaceuticals Inc. Aktie
German listing (Frankfurt) of ACADIA Pharmaceuticals Inc. · home listing NASDAQ:ACAD
Follow ACADIA Pharmaceuticals Inc. into a list and get an email when it puts out news.
Share price · FWB:DR6
€15.81 EUR -0.49 (-3.0%)
Close on Nov 20, 2026
- Day range
- €15.81 – €15.81 EURNov 20, 2026
- Market cap
- €2.72B EURAt the close on Nov 20, 2026 · price × 172.3M shares outstanding
- 52-week range
- €15.81 – €25.94 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €505 EURMedian day 0 shares · 55 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ACAD · Home | $17.11 USD | -0.72 (-4.0%) | 1,903,306 | $17.47 | $17.79 | $17.05 | $17.83 | Close on Nov 20, 2026 |
| Frankfurt:DR6 | €15.81 EUR | -0.495 (-3.0%) | — | €15.81 | €15.81 | €15.81 | €16.31 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:DR6 · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €18.65 | -0.575 | -3.0% | €18.94 | €18.97 | €18.58 | 0 | |
| €19.23 | +0.992 | +5.4% | €19.11 | €19.26 | €18.94 | 0 | |
| €18.24 | +0.013 | +0.1% | €18.22 | €18.39 | €17.96 | 1,050 | |
| €18.22 | -0.116 | -0.6% | €18.07 | €18.32 | €17.99 | 0 | |
| €18.34 | -0.226 | -1.2% | €18.47 | €18.49 | €18.07 | 0 | |
| €18.56 | +0.033 | +0.2% | €18.43 | €18.56 | €18.43 | 0 | |
| €18.53 | +0.692 | +3.9% | €18.08 | €18.55 | €17.92 | 0 | |
| €17.84 | +0.28 | +1.6% | €17.86 | €17.90 | €17.79 | 0 | |
| €17.56 | +0.08 | +0.5% | €17.53 | €17.63 | €17.46 | 0 | |
| €17.48 | -0.088 | -0.5% | €17.54 | €17.57 | €17.43 | 0 | |
| €17.57 | -0.39 | -2.2% | €17.86 | €17.88 | €17.53 | 0 | |
| €17.96 | +0.058 | +0.3% | €17.71 | €18.20 | €17.54 | 0 | |
| €17.90 | +0.112 | +0.6% | €18.03 | €18.08 | €17.90 | 0 | |
| €17.79 | +0.418 | +2.4% | €17.61 | €17.79 | €17.41 | 0 | |
| €17.37 | +0.144 | +0.8% | €17.06 | €17.38 | €16.98 | 0 | |
| €17.23 | +0.149 | +0.9% | €17.36 | €17.42 | €17.15 | 0 | |
| €17.08 | +0.696 | +4.2% | €17.08 | €17.08 | €17.08 | 0 | |
| €16.38 | -0.774 | -4.5% | €16.38 | €16.38 | €16.38 | 0 | |
| €17.15 | -0.455 | -2.6% | €17.15 | €17.15 | €17.15 | 0 | |
| €17.61 | +0.33 | +1.9% | €17.61 | €17.61 | €17.61 | 0 | |
| €17.28 | -0.076 | -0.4% | €17.28 | €17.28 | €17.28 | 0 | |
| €17.36 | -0.081 | -0.5% | €17.36 | €17.36 | €17.36 | 0 | |
| €17.44 | -0.394 | -2.2% | €17.44 | €17.44 | €17.44 | 0 | |
| €17.83 | +0.083 | +0.5% | €17.83 | €17.83 | €17.83 | 0 | |
| €17.75 | +0.299 | +1.7% | €17.75 | €17.75 | €17.75 | 0 | |
| €17.45 | -0.307 | -1.7% | €17.45 | €17.45 | €17.45 | 0 | |
| €17.76 | +0.082 | +0.5% | €17.76 | €17.76 | €17.76 | 0 | |
| €17.67 | -0.241 | -1.3% | €17.67 | €17.67 | €17.67 | 0 | |
| €17.91 | -0.049 | -0.3% | €17.91 | €17.91 | €17.91 | 0 | |
| €17.96 | -1.345 | -7.0% | €17.96 | €17.96 | €17.96 | 0 | |
| €19.31 | -2.782 | -12.6% | €19.31 | €19.31 | €19.31 | 0 | |
| €22.09 | -0.965 | -4.2% | €22.09 | €22.09 | €22.09 | 0 | |
| €23.06 | +0.282 | +1.2% | €23.06 | €23.06 | €23.06 | 0 | |
| €22.77 | -0.961 | -4.0% | €22.77 | €22.77 | €22.77 | 0 | |
| €23.73 | +0.056 | +0.2% | €23.73 | €23.73 | €23.73 | 0 | |
| €23.68 | -0.118 | -0.5% | €23.68 | €23.68 | €23.68 | 0 | |
| €23.80 | +0.806 | +3.5% | €23.80 | €23.80 | €23.80 | 0 | |
| €22.99 | -0.633 | -2.7% | €22.99 | €22.99 | €22.99 | 0 | |
| €23.62 | -0.029 | -0.1% | €23.62 | €23.62 | €23.62 | 0 | |
| €23.65 | -0.022 | -0.1% | €23.65 | €23.65 | €23.65 | 0 | |
| €23.67 | +0.21 | +0.9% | €23.67 | €23.67 | €23.67 | 0 | |
| €23.46 | -0.161 | -0.7% | €23.46 | €23.46 | €23.46 | 0 | |
| €23.63 | -0.059 | -0.2% | €23.63 | €23.63 | €23.63 | 0 | |
| €23.68 | -0.303 | -1.3% | €23.68 | €23.68 | €23.68 | 0 | |
| €23.99 | +0.231 | +1.0% | €23.99 | €23.99 | €23.99 | 0 | |
| €23.76 | -0.941 | -3.8% | €23.76 | €23.76 | €23.76 | 0 | |
| €24.70 | -0.015 | -0.1% | €24.70 | €24.70 | €24.70 | 0 | |
| €24.71 | -0.126 | -0.5% | €24.71 | €24.71 | €24.71 | 0 | |
| €24.84 | +0.125 | +0.5% | €24.84 | €24.84 | €24.84 | 0 | |
| €24.71 | -0.419 | -1.7% | €24.72 | €24.72 | €24.67 | 390 | |
| €25.13 | -0.332 | -1.3% | €25.13 | €25.13 | €25.13 | 0 | |
| €25.46 | -0.473 | -1.8% | €25.46 | €25.46 | €25.46 | 0 | |
| €25.94 | +0.661 | +2.6% | €25.94 | €25.94 | €25.94 | 0 | |
| €25.28 | +0.275 | +1.1% | €25.28 | €25.28 | €25.28 | 0 | |
| €25.00 | +0.439 | +1.8% | €25.00 | €25.00 | €25.00 | 0 | |
| €24.56 | -0.969 | -3.8% | €24.56 | €24.56 | €24.56 | 0 | |
| €25.53 | -0.247 | -1.0% | €25.53 | €25.53 | €25.53 | 0 |
- Ticker
- Frankfurt:DR6
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 17, 2026
Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Latest earnings call · Nov 4, 2026
ACADIA Pharmaceuticals (NASDAQ:ACAD) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 4, 2026
Q3 2026 Earnings Presentation
Earnings · 25 slides
Latest news
Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results
Nov 4, 2026
Closed €19.23 (+5.4%) on Nov 5, 2026
Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026
Oct 28, 2026
Closed €18.53 (+3.9%) on Oct 29, 2026
Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026
Oct 21, 2026
Closed €17.96 (+0.3%) on Oct 22, 2026
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041
Sep 28, 2026
Closed €17.91 (-0.3%) on Sep 29, 2026
ACADIA Pharmaceuticals Inc. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 30 in the last 12 months · 200 in all · newest Nov 17, 2026 · oldest 2019
- Calls
- 27 calls with a replay · 27 with a transcript · latest Nov 4, 2026
- Decks
- 32 decks · latest Nov 4, 2026
Where ACADIA Pharmaceuticals Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ACAD · Home listing | NASDAQ | United States | USD |
| gettex:DR6 | gettex | Germany | EUR |
| Tradegate:DR6 | Tradegate | Germany | EUR |
| BMV:ACAD | BMV | Mexico | MXN |
| LS Exchange:603035 | LS Exchange | Germany | EUR |
| Lang & Schwarz:603035 | Lang & Schwarz | Germany | EUR |
| Frankfurt:DR6 · This page | Frankfurt | Germany | EUR |
| BIVA:ACAD | BIVA | Mexico | MXN |
| BOATS:ACAD | BOATS | United States | USD |
| LSE:0A4W | LSE | United Kingdom | USD |
| Dusseldorf:DR6 | Dusseldorf | Germany | EUR |
| Munich:DR6 | Munich | Germany | EUR |
| Stuttgart:DR6 | Stuttgart | Germany | EUR |
Valuation
P/E 8.2× against a median of 16.5×: 2nd lowest of 8 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $2.05B USD
- P/E
- 8.2×
- EV/sales
- 1.7×
- EV/EBITDA
- 15.5×
- Price/book
- 2.1×
- Gross margin
- 90.5%
- Operating margin
- 10.2%
- Net margin
- 30.1%
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 0.40
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc. · NASDAQ:ACAD | US$2.96B | US$2.05B | 8.2× | 1.7× | 15.5× | 2.1× | 30.1% | 0.1× | 0.40 |
| Hualan Biological Engineering Inc. Class A · SZSE:002007 | US$3.13B | US$2.62B | 35.6× | 4.6× | n/a | 2.0× | 15.4% | 0.0× | n/a |
| Xeris Biopharma Holdings, Inc. · NASDAQ:XERS | US$3.10B | US$3.16B | n/a | 8.6× | 58.9× | 63.5× | −1.8% | 3.9× | 0.11 |
| Bausch Health Companies Inc. · TSX:BHC | US$3.08B | US$21.23B | n/a | 1.9× | n/a | n/a | −7.6% | n/a | 0.65 |
| Rubicon Research Limited · NSE:RUBICON | US$3.07B | US$3.05B | 98.7× | 14.6× | 62.8× | 22.1× | 14.9% | 0.1× | n/a |
| Jilin Aodong Pharmaceutical Group Co., Ltd. Class A · SZSE:000623 | US$2.98B | US$2.56B | 6.6× | 7.6× | n/a | 0.6× | 133.7% | 0.0× | n/a |
| ADMA Biologics Inc · NASDAQ:ADMA | US$2.92B | US$2.99B | 16.0× | 5.8× | 12.0× | 6.7× | 35.1% | 0.5× | 0.05 |
| Chengdu Kanghong Pharmaceutical Group Co., Ltd. Class A · SZSE:002773 | US$2.90B | US$1.94B | 21.1× | 3.1× | n/a | 2.0× | 22.1% | 0.0× | n/a |
| Telix Pharmaceuticals Limited · ASX:TLX | US$2.90B | US$3.22B | n/a | 4.0× | 63.0× | 5.9× | −0.9% | 1.2× | n/a |
| China Medical System Holdings Ltd. · HKEX:867 | US$2.87B | US$2.13B | 12.8× | 1.7× | 7.7× | 1.1× | 18.1% | 0.1× | n/a |
| Joincare Pharmaceutical Group Industry Co., Ltd. Class A · SSE:600380 | US$2.80B | US$1.16B | 16.5× | 0.6× | n/a | 1.3× | 8.4% | 0.1× | n/a |
| Median of the others | US$2.95B | US$2.81B | 16.5× | 4.3× | 58.9× | 2.0× | 15.2% | 0.1× | 0.11 |
Forecasts
10 strong buy · 4 buy · 5 hold · 1 strong sell · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 30.32 USD · Analysts' mean
- EPS, year to Dec 2026
- 0.77 · 13 analysts
- Revenue, year to Dec 2026
- 1.28B · 19 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Catherine Owen Adams | Chief Executive Officer |
| Mark Schneyer | Chief Financial Officer |
| Jennifer J. Rhodes | Chief Legal Officer and Secretary |
| Carl Segerstrom | Chief People Officer |
| Konstantina Katcheves | Chief Business and Strategy Officer |
| Scott Cenci | Chief Information and Data Officer |
Board
| Director | Role |
|---|---|
| Stephen Biggar | Chairman |
| Adora Ndu | Director |
| Edmund Harrigan | Director |
| Elizabeth Garofalo | Director |
| James Daly | Director |
| Jonathan M. Poole | Director |
| Julian Baker | Director |
| Laura Brege | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| ACADIA Pharmaceuticals (NASDAQ:ACAD) Q3 2026 Earnings Call | Wed, Nov 04, 2026 · 4:30 PM ET | Replay |
| ACADIA Pharmaceuticals (NASDAQ:ACAD) Q2 2026 Earnings Call | Tue, Aug 04, 2026 · 4:30 PM ET | Replay |
| ACADIA Pharmaceuticals (NASDAQ:ACAD) Q1 2026 Earnings Call | Wed, May 06, 2026 · 4:30 PM ET | Replay |
| ACADIA Pharmaceuticals (NASDAQ:ACAD) Q4 2025 Earnings Call | Wed, Feb 25, 2026 · 4:30 PM ET | Replay |
| ACADIA Pharmaceuticals (NASDAQ:ACAD) Q3 2025 Earnings Call | Wed, Nov 05, 2025 · 4:30 PM ET | Replay |
| ACADIA Pharmaceuticals (NASDAQ:ACAD) Q2 2025 Earnings Call | Wed, Aug 06, 2025 · 4:30 PM ET | Replay |
| ACADIA Pharmaceuticals (NASDAQ:ACAD) Q1 2025 Earnings Call | Wed, May 07, 2025 · 4:30 PM ET | Replay |
| ACADIA Pharmaceuticals (NASDAQ:ACAD) Q4 2024 Earnings Call | Wed, Feb 26, 2025 · 4:30 PM ET | Replay |
| ACADIA Pharmaceuticals (NASDAQ:ACAD) Q3 2024 Earnings Call | Wed, Nov 06, 2024 · 4:30 PM ET | Replay |
| ACADIA Pharmaceuticals (NASDAQ:ACAD) Q2 2024 Earnings Call | Tue, Aug 06, 2024 · 4:30 PM ET | Replay |
All 27 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · After close | −1.1% |
| Q2 2026 | Aug 4, 2026 · After close | +6.1% |
| Q1 2026 | May 6, 2026 · After close | +5.0% |
| Q4 2025 | Mar 2, 2026 | −8.4% |
| Q3 2025 | Nov 5, 2025 · After close | −3.0% |
| Q2 2025 | Aug 6, 2025 · After close | +2.5% |
| Q1 2025 | May 7, 2025 · After close | +14.3% |
| Q4 2024 | Feb 25, 2025 · Before open | −2.4% |
| Q3 2024 | Nov 6, 2024 · After close | +8.9% |
| Q2 2024 | Aug 6, 2024 · After close | −19.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · After close | −11.2% |
| Q4 2023 | Feb 27, 2024 · After close | −9.9% |
| Q3 2023 | Nov 2, 2023 · After close | +4.7% |
| Q2 2023 | Aug 2, 2023 · After close | −6.8% |
| Q1 2023 | May 8, 2023 · After close | −0.6% |
| Q4 2022 | Feb 27, 2023 · After close | +6.7% |
| Q3 2022 | Nov 2, 2022 · After close | −7.0% |
| Q2 2022 | Aug 8, 2022 · After close | −2.4% |
| Q1 2022 | May 4, 2022 · After close | −5.3% |
| Q4 2021 | Feb 28, 2022 · After close | −1.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 25 slides | Nov 4, 2026 |
| Technical Presentation (September 2026) | Technical | 19 slides | Sep 24, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 21 slides | Aug 4, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 20 slides | Feb 25, 2026 |
| Clinical Trials on Alzheimer's Disease (CTAD) 2026 | Conference | 14 slides | 2026 |
| Q3 2025 Earnings Presentation | Earnings | 17 slides | Nov 5, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 20 slides | Aug 6, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 19 slides | May 7, 2025 |
| Q4 2024 Earnings Presentation | Earnings | 25 slides | Feb 26, 2025 |
| Q3 2024 Earnings Presentation | Earnings | 22 slides | Nov 6, 2024 |
All 32 decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.07B | 957.8M | 726.4M | 517.2M | 484.1M | 441.8M | 339.1M | 223.8M | 124.9M | 17.3M |
| Cost of revenue | 89.0M | 81.8M | 41.6M | 10.2M | 19.1M | 10.2M | 11.3M | 12.4M | 9.08M | 3.08M |
| Gross profit | 982.5M | 876.0M | 684.8M | 507.1M | 473.3M | 431.5M | 327.7M | 211.4M | 115.8M | 14.3M |
| Research and development | 328.8M | 303.2M | 351.6M | 361.6M | 239.4M | 319.1M | 240.4M | 187.2M | 149.2M | 99.3M |
| Selling, general and administrative | 548.9M | 488.4M | 406.6M | 369.1M | 396.0M | 388.7M | 325.6M | 265.8M | 255.1M | 186.5M |
| Operating income | 104.8M | 230.8M | -73.4M | -223.6M | -170.4M | -286.6M | -246.5M | -247.4M | -292.4M | -272.8M |
| Depreciation and amortization | 871.0K | 920.0K | 1.46M | 2.03M | 2.24M | 1.46M | 1.29M | 1.53M | 1.24M | 843.0K |
| EBITDA | 105.7M | 231.7M | -71.9M | -221.6M | -168.2M | -285.1M | -245.3M | -245.9M | -291.2M | -272.0M |
| Interest expense | 6.61M | 6.26M | 8.54M | 14.9M | 0 | 0 | 0 | |||
| Income before tax | 138.9M | 258.1M | -51.0M | -213.4M | -167.5M | -281.0M | -234.4M | -243.9M | -288.3M | -270.1M |
| Income tax | -252.1M | 31.6M | 10.3M | 2.53M | 351.0K | 611.0K | 876.0K | 1.26M | 1.12M | 1.34M |
| Net income | 391.0M | 226.5M | -61.3M | -216.0M | -167.9M | -281.6M | -235.3M | -245.2M | -289.4M | -271.4M |
| Earnings per share, basic | 2.32 | 1.37 | -0.37 | -1.34 | -1.05 | -1.79 | -1.60 | -1.94 | -2.36 | -2.34 |
| Earnings per share, diluted | 2.30 | 1.36 | -0.37 | -1.34 | -1.05 | -1.79 | -1.60 | -1.94 | -2.36 | -2.34 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 177.7M | 319.6M | 188.7M | 114.8M | 147.4M | 326.0M | 189.7M | 134.8M | 69.4M | 163.6M |
| Short-term investments | 642.0M | 436.4M | 250.2M | 302.0M | 373.3M | 305.9M | 507.7M | 338.8M | 271.9M | 365.4M |
| Receivables | 121.5M | 98.7M | 98.3M | 62.2M | 64.4M | 48.2M | 35.8M | 26.1M | 17.3M | 5.90M |
| Inventory | 111.4M | 91.7M | 40.4M | 11.6M | 14.1M | 9.68M | 6.34M | 4.07M | 5.25M | 4.17M |
| Current assets | 1.06B | 938.3M | 616.1M | 507.9M | 617.8M | 717.6M | 760.3M | 526.1M | 373.5M | 547.9M |
| Property, plant and equipment | 7.51M | 4.21M | 4.61M | 6.02M | 8.05M | 9.16M | 3.18M | 3.31M | 2.66M | 3.08M |
| Goodwill | 1 | 0 | 0 | |||||||
| Total assets | 1.56B | 1.19B | 749.0M | 587.8M | 700.1M | 782.6M | 783.2M | 540.2M | 384.5M | 561.2M |
| Accounts payable | 10.9M | 16.2M | 17.5M | 12.7M | 6.88M | 8.49M | 7.22M | 3.17M | 8.79M | 3.91M |
| Current liabilities | 277.1M | 394.9M | 254.3M | 125.6M | 96.1M | 106.0M | 74.8M | 59.6M | 49.0M | 42.6M |
| Long-term debt | 0 | 0 | ||||||||
| Total debt | 52.2M | 52.0M | 57.2M | 62.0M | 64.4M | 49.5M | 9.79M | |||
| Total liabilities | 336.8M | 455.0M | 317.2M | 187.4M | 159.2M | 155.6M | 84.0M | 61.1M | 49.2M | 42.7M |
| Shareholders' equity | 1.23B | 732.8M | 431.8M | 400.4M | 540.9M | 627.0M | 699.1M | 479.1M | 335.3M | 518.4M |
| Shares outstanding | 170.3M | 166.7M | 164.7M | 162.1M | 161.0M | 159.6M | 155.3M | 143.9M | 124.4M | 121.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 109.8M | 157.7M | 16.7M | -114.0M | -125.7M | -136.2M | -151.1M | -167.5M | -217.8M | -208.4M |
| Capital spending | -4.69M | -523.0K | -50.0K | 0 | -1.12M | -7.59M | -1.13M | -2.10M | -812.0K | -1.51M |
| Free cash flow | 105.1M | 157.2M | 16.7M | -114.0M | -126.8M | -143.8M | -152.3M | -169.6M | -218.6M | -209.9M |
| Cash from investing | -302.6M | -30.5M | 32.0M | 73.2M | -71.1M | 192.5M | -165.8M | -71.5M | 92.5M | -261.9M |
| Cash from financing | 49.9M | 6.84M | 25.1M | 8.20M | 18.2M | 81.0M | 371.8M | 306.6M | 31.2M | 533.8M |
| Dividends paid | 0 | 0 | ||||||||
| Share buybacks | 18.2M | 81.0M | 371.8M | 306.6M | 31.2M | 518.9M | ||||
| Change in cash | -142.8M | 133.9M | 73.8M | -32.6M | -178.6M | 137.3M | 54.9M | 67.7M | -94.1M | 63.5M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 10, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 23, 2026 | Management or board change | SEC |
| 8-K · Current report | Sep 24, 2026 | Current report | SEC |
| 8-K · Current report | Sep 11, 2026 | Current report | SEC |
| 4 · Change in ownership | Aug 7, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 7, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 5, 2026 | Other filings | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Aug 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 31, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 26, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Jun 10, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jun 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 8-K · Current report | May 29, 2026 | Management or board change | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 26, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2026 | Results | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 30, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 28, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 23, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 23, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 4, 2026 | Management or board change | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 26, 2026 | Big-stake notice | SEC |
| 10-K · Annual report | Feb 25, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 25, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2026 | Results | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 10, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| 8-K · Current report | Nov 3, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 18, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| 8-K · Current report | Jun 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 4, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 8-K · Current report | May 29, 2025 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | May 27, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 21, 2025 | Other filings | SEC |
| 8-K · Current report | May 20, 2025 | Material contract | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | May 16, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 14, 2025 | Other filings | SEC |
| S-3 · Registration statement | May 9, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2025 | Results | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 25, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 16, 2025 | Current report | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 6, 2025 | Other filings | SEC |
| 10-K · Annual report | Feb 27, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 7, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 11, 2024 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Dec 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 10, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 20, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Nov 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 25, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Sep 23, 2024 | Offer document | SEC |
| 8-K · Current report | Sep 23, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| S-8 POS | Aug 20, 2024 | Offer document | SEC |
| S-8 POS | Aug 20, 2024 | Offer document | SEC |
| S-8 POS | Aug 20, 2024 | Offer document | SEC |
| S-8 POS | Aug 20, 2024 | Offer document | SEC |
| S-8 POS | Aug 20, 2024 | Offer document | SEC |
| S-8 POS | Aug 20, 2024 | Offer document | SEC |
| S-8 POS | Aug 20, 2024 | Offer document | SEC |
| S-8 POS | Aug 20, 2024 | Offer document | SEC |
| S-8 POS | Aug 20, 2024 | Offer document | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2024 | Results | SEC |
| 4 · Change in ownership | Jun 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 31, 2024 | Insider trade | SEC |
| 8-K · Current report | May 29, 2024 | Management or board change | SEC |
| S-8 POS | May 29, 2024 | Offer document | SEC |
| S-8 POS | May 29, 2024 | Offer document | SEC |
| S-8 POS | May 29, 2024 | Offer document | SEC |
| S-8 POS | May 29, 2024 | Offer document | SEC |
| S-8 POS | May 29, 2024 | Offer document | SEC |
| S-8 POS | May 29, 2024 | Offer document | SEC |
| S-8 POS | May 29, 2024 | Offer document | SEC |
| S-8 POS | May 29, 2024 | Offer document | SEC |
| S-8 POS | May 29, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | May 29, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2024 | Results | SEC |
| 4 · Change in ownership | May 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 3, 2024 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| 3 · Initial statement of ownership | Apr 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 27, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 11, 2024 | Current report | SEC |
| 4 · Change in ownership | Feb 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2024 | Insider trade | SEC |
| 10-K · Annual report | Feb 27, 2024 | Annual report | SEC |
| 8-K · Current report | Feb 27, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 8, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 30, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 26, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 15, 2023 | Other filings | SEC |
| 4 · Change in ownership | Nov 28, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2023 | Insider trade | SEC |
This page holds 200 of 1,001 filings. Open Filings
Cap table
Built by 6ix from ACADIA Pharmaceuticals Inc.’s releases · as of Oct 28, 2026
- Common shares
- 172,828,972
- Fully diluted
- 172,828,972
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 172,828,972 | Oct 28, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 28, 2026 | 172,828,972 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Felix Baker Other companies: BeOne Medicines Ltd. Class A (Director · Since at least Nov 6, 2026); Denali Therapeutics Inc. (Director · Since at least Jun 3, 2025); Replimune Group, Inc. (Director · Since at least Mar 5, 2025); Bicycle Therapeutics PLC (Director · Since at least Apr 18, 2024); Kymera Therapeutics, Inc. (Chairman · Since at least Mar 28, 2024); vTv Therapeutics Inc. (Director · Since at least Feb 27, 2024); Madrigal Pharmaceuticals, Inc. (Director · Since at least Jun 15, 2023); TScan Therapeutics, Inc. (Director · Since at least Jul 15, 2021); DBV Technologies SA (Director · Since at least Jan 1, 2021); Prelude Therapeutics Incorporated (Director · Since at least Mar 27, 2020); IGM Biosciences Inc (Director · Since at least Sep 17, 2019); Kodiak Sciences Inc (Director · Since at least Oct 3, 2018); Kiniksa Pharmaceuticals International, plc (Lead Director · Since at least Feb 9, 2018); Incyte Corporation (Director · Since at least Jan 4, 2008); Immunocore Holdings plc (Director · May 28, 2024 – May 15, 2025 · Past); Spyre Therapeutics, Inc. (Director · Feb 23, 2021 – Jun 8, 2021 · Past); Talis Biomedical Corp (Director · Nov 2, 2020 – Jun 9, 2023 · Past); Zymeworks Inc. (Director · Mar 16, 2020 – May 8, 2020 · Past); Neurogene Inc. (Director · May 8, 2017 – Dec 18, 2023 · Past); Alexion Pharmaceuticals Inc (Director · Jun 22, 2015 – May 14, 2020 · Past); Aceragen Inc. (Director · Mar 10, 2014 – Apr 1, 2019 · Past); Ardea Biosciences Inc (Director · Feb 8, 2010 – Jun 19, 2012 · Past); Synageva BioPharma Corp (Director · Aug 14, 2007 – Jun 22, 2015 · Past); Neurogen Corp (Director · Jun 7, 2007 – Jul 25, 2008 · Past); Seagen Inc (Director · May 25, 2007 – Dec 14, 2023 · Past); Genomic Health Inc (Director · May 21, 2007 – Oct 1, 2019 · Past) | Director · Since at least Jan 18, 2013 |
| Julian Baker Other companies: Denali Therapeutics Inc. (Director · Since at least Jun 3, 2025); Replimune Group, Inc. (Director · Since at least Mar 5, 2025); Bicycle Therapeutics PLC (Director · Since at least Apr 18, 2024); Kymera Therapeutics, Inc. (Director · Since at least Mar 28, 2024); vTv Therapeutics Inc. (Director · Since at least Feb 27, 2024); Madrigal Pharmaceuticals, Inc. (Director · Since at least Jun 15, 2023); TScan Therapeutics, Inc. (Director · Since at least Jul 15, 2021); DBV Technologies SA (Director · Since at least Jan 1, 2021); Prelude Therapeutics Incorporated (Director · Since at least Mar 27, 2020); IGM Biosciences Inc (Director · Since at least Sep 17, 2019); Kodiak Sciences Inc (Director · Since at least Oct 3, 2018); Kiniksa Pharmaceuticals International, plc (Director · Since at least Feb 9, 2018); Incyte Corporation (Managing Partner, Baker Brothers Investments | Chairman, Incyte · Since at least Apr 25, 2006); Immunocore Holdings plc (Director · May 28, 2024 – May 15, 2025 · Past); Spyre Therapeutics, Inc. (Director · Feb 23, 2021 – Jun 8, 2021 · Past); Talis Biomedical Corp (Director · Nov 2, 2020 – Jun 9, 2023 · Past); Zymeworks Inc. (Director · Mar 16, 2020 – May 8, 2020 · Past); Neurogene Inc. (Director · May 8, 2017 – Dec 18, 2023 · Past); Alexion Pharmaceuticals Inc (Director · Jun 22, 2015 – May 14, 2020 · Past); Aceragen Inc. (Director · Mar 10, 2014 – Apr 1, 2019 · Past); Ardea Biosciences Inc (Director · Apr 6, 2010 – Jun 19, 2012 · Past); Seagen Inc (Director · Jun 9, 2006 – Dec 14, 2023 · Past); Innoviva, Inc. (Director · Apr 26, 2006 – Apr 26, 2006 · Past); Genomic Health Inc (Director · Apr 25, 2006 – Oct 1, 2019 · Past); Synageva BioPharma Corp (Director · Apr 25, 2006 – Jun 22, 2015 · Past); Neurogen Corp (Director · Mar 15, 2006 – Dec 15, 2009 · Past) | Director · Since at least Jan 18, 2013 |
| Laura Brege Other companies: Edgewise Therapeutics, Inc. (Director · Since at least Mar 25, 2021); Mirum Pharmaceuticals, Inc. (Board Member · Since at least Jul 17, 2019); Pacira BioSciences, Inc. (Director · Since at least Jun 6, 2016); Aratana Therapeutics Inc (Director · Jun 24, 2016 – Jul 27, 2018 · Past); Portola Pharmaceuticals Inc (Director · Jun 17, 2016 – Jul 2, 2020 · Past); Dynavax Technologies Corporation (Director · May 31, 2016 – May 30, 2019 · Past) | Director · Since at least Jun 10, 2016 |
| Stephen Davis Other companies: Bellicum Pharmaceuticals Inc (Director · Jul 13, 2015 – Jan 3, 2023 · Past); Furiex Pharmaceuticals Inc (Director · May 24, 2013 – Jul 2, 2014 · Past); Ardea Biosciences Inc (EVP & COO · Apr 6, 2010 – Jun 19, 2012 · Past); Heron Therapeutics, Inc. (Director · Feb 17, 2010 – Dec 16, 2022 · Past); Synageva BioPharma Corp (Director · Jun 27, 2007 – Jun 22, 2015 · Past); Neurogen Corp (President, CEO, Director · Dec 15, 2006 – Jul 25, 2008 · Past) | CEO, Director · Jul 15, 2014 – Aug 16, 2024 · Past |
| Daniel B Soland Other companies: Aceragen Inc. (CHIEF OPERATING OFFICER · Jan 4, 2021 – Jul 6, 2022 · Past); DBV Technologies SA (Director · Jan 1, 2021 – Aug 1, 2023 · Past); KalVista Pharmaceuticals, Inc. (Director · Apr 22, 2019 – Sep 30, 2021 · Past); Viropharma Inc (VP, Chief Operating Officer · Nov 6, 2006 – Jan 24, 2014 · Past) | Director · Since at least Mar 20, 2015 |
| Edmund Harrigan Other companies: Incyte Corporation (Director · Since at least Dec 16, 2019); Karuna Therapeutics Inc (Director · Jun 27, 2019 – Aug 12, 2020 · Past); PhaseBio Pharmaceuticals Inc (Director · Dec 13, 2018 – May 19, 2023 · Past); Bellicum Pharmaceuticals Inc (Director · Feb 20, 2018 – Jun 13, 2019 · Past) | Director · Since at least Nov 25, 2015 |
| Elena Ridloff Other companies: Immunic, Inc. (Director · Since at least Aug 6, 2026); Sionna Therapeutics, Inc. (CFO and CBO · Since at least Feb 6, 2025); Kymera Therapeutics, Inc. (Director · Since at least Mar 12, 2021); Kronos Bio Inc (Director · Since at least Oct 8, 2020) | EVP and CFO · Jan 6, 2021 – Apr 29, 2021 · Past |
| Alan G Walton Other companies: Ocata Therapeutics Inc (Director · Jan 26, 2006 – Jan 26, 2006 · Past); Avalon Pharmaceuticals Inc (Director · Dec 26, 2005 – Jan 2, 2008 · Past); Alexandria Real Estate Equities, Inc. (Director · Jan 14, 2005 – Dec 30, 2011 · Past) | Director · Jun 13, 2006 – Jun 12, 2009 · Past |
| Elizabeth Garofalo Other companies: Alector, Inc. (Board Member · Since at least Sep 23, 2021); Xenon Pharmaceuticals Inc. (Director · Since at least Jun 3, 2021); Exicure, Inc. (Director · Mar 5, 2021 – Jun 13, 2022 · Past) | Director · Since at least Sep 29, 2020 |
| James Daly Other companies: Halozyme Therapeutics, Inc. (Director · Since Sep 30, 2026); Cytokinetics, Incorporated (Director · Since at least Aug 19, 2025); Madrigal Pharmaceuticals, Inc. (Director · Since at least Jun 20, 2025) | Director · Since at least May 29, 2025 |
All 38 people
| Person | Seat |
|---|---|
| Jennifer J. Rhodes Other companies: Elicio Therapeutics, Inc. (See Remarks · Feb 4, 2021 – Mar 2, 2022 · Past); Adamas Pharmaceuticals Inc (CBO, GC & Compliance Officer · Apr 11, 2016 – Jun 20, 2019 · Past); Medivation Inc (GC & Corporate Secretary · Mar 26, 2013 – Mar 16, 2015 · Past) | Chief Legal Officer and Secretary · Since at least Feb 6, 2024 |
| Michael Yang Other companies: Ionis Pharmaceuticals, Inc. (Director · Since at least Dec 14, 2023); Pacira BioSciences, Inc. (Director · Since at least Oct 6, 2023); Akcea Therapeutics Inc (Director · Sep 20, 2019 – Oct 12, 2020 · Past) | EVP and CCO · Apr 18, 2018 – Jan 6, 2021 · Past |
| Adams Catherine Owen Other companies: Agios Pharmaceuticals, Inc. (Director · Since at least Jun 13, 2023); OptiNose (Director · Jul 29, 2020 – Jun 6, 2024 · Past) | Chief Executive Officer, Director · Since at least Sep 23, 2024 |
| Douglas J. Williamson Other companies: Vistagen Therapeutics, Inc. (Director · Since at least Jul 29, 2026); Avadel Pharmaceuticals PLC (Chief Medical Officer · Feb 14, 2022 – Feb 14, 2022 · Past) | Executive VP, Research & Dev · Feb 1, 2023 – Feb 10, 2023 · Past |
| Todd S. Young Other companies: Acadia Healthcare Company, Inc. (Chief Financial Officer · Since at least Oct 27, 2025); Elanco Animal Health Incorporated (SEE REMARKS · Nov 1, 2018 – Mar 3, 2025 · Past) | EVP AND CFO · Aug 22, 2016 – Oct 15, 2018 · Past |
| Adora Ndu Other companies: DBV Technologies SA (Board Member · Since at least May 19, 2021) | Director · Since at least Oct 12, 2022 |
| Brendan Teehan Other companies: Pacira BioSciences, Inc. (Chief Commercial Officer · Since at least Jan 21, 2025) | EVP, COO, HEAD OF COMMERCIAL · Nov 1, 2021 – Nov 17, 2024 · Past |
| Brian Lundstrom Other companies: International Stem Cell Corporation (President · Nov 5, 2009 – Dec 17, 2010 · Past) | Sr. VP, Bus. Development · Mar 10, 2006 – Mar 7, 2008 · Past |
| Elizabeth H Z Thompson Other companies: IGM Biosciences Inc (Director · Since at least Oct 3, 2023) | EVP, Head of Research & Dev · Since at least Apr 4, 2024 |
| John Joseph Kaiser Other companies: Avalo Therapeutics, Inc. (Chief Business Officer · Oct 14, 2015 – Aug 18, 2017 · Past) | VP, Strat. Mrkting & Com. Dev. · Mar 7, 2008 – Oct 20, 2008 · Past |
| Jonathan M. Poole Other companies: Evelo Biosciences, Inc. (CFO · May 8, 2018 – Jan 28, 2020 · Past) | Director · Since at least Mar 3, 2026 |
| Roger Mills Other companies: Addex Therapeutics Ltd (Board Director and Chief Medical Officer · Since at least Mar 18, 2026) | EVP, DEVELOPMENT AND CMO · Jun 30, 2006 – Mar 20, 2015 · Past |
| Srdjan R Stankovic Other companies: Neurogen Corp (Exec VP and CDO · Apr 14, 2008 – Jul 25, 2008 · Past) | President · Nov 25, 2015 – Nov 19, 2022 · Past |
| Stephen Biggar Other companies: Kiniksa Pharmaceuticals International, plc (Director · Since at least Nov 5, 2026) | Chairman · Since at least Mar 3, 2026 |
| Thomas Garner Other companies: Lexicon Pharmaceuticals, Inc. (SVP, Chief Commercial Officer · Oct 9, 2023 – Feb 8, 2024 · Past) | EVP, Chief Commercial Officer · Since at least Dec 9, 2024 |
| Thomas H Aasen Other companies: Avalo Therapeutics, Inc. (Director · Jan 10, 2016 – Jun 30, 2017 · Past) | EXEC VP, CFO AND CBO · May 9, 2007 – Apr 4, 2014 · Past |
| Uli Hacksell Other companies: Avalo Therapeutics, Inc. (Director · Oct 14, 2015 – Mar 31, 2020 · Past) | CEO, Director · May 16, 2007 – Feb 17, 2015 · Past |
| Austin D Kim | EVP,General Counsel, Secretary · Jul 18, 2018 – Jan 6, 2024 · Past |
| Carl Segerstrom | Chief People Officer · Since at least Jul 6, 2026 |
| Catherine Owen Adams | Chief Executive Officer · Since at least Sep 28, 2026 |
| Glenn Baity | EVP AND GC · Oct 4, 2017 – Apr 18, 2018 · Past |
| James Kihara | PRINCIPAL ACCOUNTING OFFICER · Since at least Jun 23, 2020 |
| Konstantina Katcheves | Chief Business and Strategy Officer · Since at least Nov 5, 2025 |
| Leslie L Iversen | Director · Jun 13, 2006 – Apr 18, 2016 · Past |
| Mark R Brann | President & CSO, Director · Jan 3, 2006 – Jun 16, 2006 · Past |
| Mark Schneyer | EVP, CHIEF FINANCIAL OFFICER · Since at least Apr 5, 2025 |
| Scott Cenci | Chief Information and Data Officer · Since at least Aug 4, 2025 |
| Torsten Rasmussen | Director · Jun 13, 2006 – Jun 15, 2015 · Past |
Log in to ask 6ix AI your own questions about ACADIA Pharmaceuticals Inc.